Parallax Volatility Advisers
AQST icon

Parallax Volatility Advisers’s Aquestive Therapeutics AQST Stock Holding History

Parallax Volatility Advisers’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,847
Closed -$36K – 2954
2021
Q1 		$36K Buy
+6,847
New +$36.4K ﹤0.01% 2987

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $5.53B AUM 25.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $136M AUM 9.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Parallax Volatility Advisers's AQST Position: Q2 2021 in Review

Parallax Volatility Advisers sold out of Aquestive Therapeutics (AQST) in Q2 2021, closing a stake of 6,847 shares — an estimated $36K sold.

Parallax Volatility Advisers first reported a position in AQST in Q1 2021 and held it in 1 quarter. The position peaked at $36K in Q1 2021. 60 funds tracked by Wall St. Rank hold AQST as of Q2 2021.

  • Parallax Volatility Advisers reported no remaining Aquestive Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Parallax Volatility Advisers sold 6,847 Aquestive Therapeutics shares in Q2 2021, an estimated $36K.
  • Parallax Volatility Advisers first reported a position in Aquestive Therapeutics in Q1 2021 and held it in 1 quarter.
  • Parallax Volatility Advisers's Aquestive Therapeutics position peaked at $36K in Q1 2021.
  • 60 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2021.

Based on Parallax Volatility Advisers's 13F filing for Q2 2021, filed 16 Aug 2021.